Khan Muhammad Asim, Mutahir Sadaf, Jabar Gauhar, Wenwei Zhao, Tariq Muhammad Atif, Almehizia Abdulrahman A, Mustafa Muhammad
School of Chemistry and Chemical Engineering, Linyi University, Linyi, 276005, China.
Department of Chemistry, University of Sialkot, Sialkot, 51300, Pakistan.
Chem Biodivers. 2024 Dec;21(12):e202401775. doi: 10.1002/cbdv.202401775. Epub 2024 Oct 22.
This study explores the capability of thiazoles as potent inhibitors of SARS-CoV-2 Mpro. Seventeen thiazoles (1-17) were screened for their linking affinity with the active site of SARS-CoV-2 Mpro and compared with the FDA-recommended antiviral drugs, Remdesivir and Baricitinib. Density Functional Theory (DFT) calculations provided electronic and energetic properties of these ligands, shedding light on their stability and reactivity. Molecular docking analysis revealed that thiazole derivatives exhibited favorable linking affinities with various functional sites of SARS-CoV-2 proteins, including spike receptor-linking zone, nucleocapsid protein N-terminal RNA linking zone, and Mpro. Notably, compounds 3, 10, and 12 displayed the best interaction with 6LZG as compared to FDA-approved antiviral drugs Remdesivir and Baricitinib, while compounds 1, 10, and 8 exhibited strong linking with 6 M3 M and also better than Remdesivir and Baricitinib. Additionally, compounds 3, 1, and 6 showed promising interactions with 6LU7 but only compound 3 performed better than Baricitinib. An ADME (Absorption, Distribution, Metabolism, and Excretion) study provided insights into the pharmacokinetics and drug-likeness of these compounds, with all ligands demonstrating good physicochemical characteristics, lipophilicity, water solubility, pharmacokinetics, drug-likeness, and medicinal chemistry attributes. The results suggest that these selected thiazole derivatives hold promise as potential candidates for further drug development.
本研究探讨了噻唑类化合物作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主蛋白酶(Mpro)有效抑制剂的能力。筛选了17种噻唑类化合物(1-17)与SARS-CoV-2 Mpro活性位点的结合亲和力,并与美国食品药品监督管理局(FDA)推荐的抗病毒药物瑞德西韦和巴瑞替尼进行比较。密度泛函理论(DFT)计算提供了这些配体的电子和能量性质,揭示了它们的稳定性和反应性。分子对接分析表明,噻唑衍生物与SARS-CoV-2蛋白的各个功能位点具有良好的结合亲和力,包括刺突受体结合区、核衣壳蛋白N端RNA结合区和Mpro。值得注意的是,与FDA批准的抗病毒药物瑞德西韦和巴瑞替尼相比,化合物3、10和12与6LZG的相互作用最佳,而化合物1、10和8与6 M3 M的结合很强,也优于瑞德西韦和巴瑞替尼。此外,化合物3、1和6与6LU7显示出有前景的相互作用,但只有化合物3的表现优于巴瑞替尼。一项吸收、分布、代谢和排泄(ADME)研究提供了这些化合物的药代动力学和类药性质的相关见解,所有配体均表现出良好的物理化学特性、亲脂性、水溶性、药代动力学、类药性质和药物化学属性。结果表明,这些选定的噻唑衍生物有望成为进一步药物开发的潜在候选物。